What Igyxos does

Igyxos Biotherapeutics is a French clinical-stage biotechnology company developing IGX12, a first-in-class humanized monoclonal antibody (mAb) designed to enhance the bioactivity of Follicle Stimulating Hormone (FSH) for the treatment of infertility in both men and women. Founded in 2017 by Dr. Marie-Christine Maurel as a spin-out from ReproPharm, the company is headquartered at the INRAe Val de Loire research center in Nouzilly, France, and operates with 1–10 employees.

IGX12 operates through a novel conformational mechanism of action: the antibody binds to both FSH and the FSH receptor, facilitating receptor interaction and significantly improving FSH receptor activation. Preclinical evidence demonstrates enhanced ovarian stimulation (3x higher output in cynomolgus monkeys) and boosted spermatogenesis (approximately 6-fold increase in motile sperm count in hypogonadal mice models). The drug candidate has a long half-life (~43 days) supportive of monthly dosing, potentially reducing injection burden relative to current FSH therapies that require multiple injections per cycle. Igyxos completed Phase 1 Single Ascending Dose (32 healthy volunteers, March 2025) and Multiple Ascending Dose (14 healthy male volunteers, December 2025) trials with favorable safety profiles and is preparing Phase 2 trials in European fertility centers for 2026.

Igyxos is pre-revenue and monetizes through future commercialization of IGX12 via fertility clinics and healthcare providers globally. Current operations are funded by approximately EUR 27 million in cumulative capital — EUR 19 million in equity (EUR 7.5M Series A led by Bpifrance in 2019) and EUR 8 million in grants, loans and repayable advances, including a EUR 5.7 million France 2030 grant awarded in October 2025. The company executes CMC and clinical work through service partnerships with Merck Biodevelopment, Baccinex, Selexis, ERBC, and CRS Berlin. Key investors include Bpifrance, GO Capital, UI Investissement, and Sofimac Innovation.

Name

Igyxos

Legal name

Igyxos S.A.

Website

https://igyxos.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

1–10 employees

Short description

Igyxos Biotherapeutics is a French clinical-stage biotechnology company developing IGX12, a first-in-class monoclonal antibody that enhances FSH bioactivity to treat infertility in both men and women, with Phase 2 trials planned for 2026.

Ownership category

akta.pro rank

Product category

Reproductive Health Biopharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

akta.pro primary industry

Reproductive Endocrinology & Infertility (IVF/Fertility) (HLAKAJAC)

Keywords

• Monoclonal antibody therapeutics
• Fertility treatment development
• Reproductive health biopharmaceuticals
• Infertility therapeutics research
• Gonadotropin enhancing antibodies

Headquarters

HQ city

Nouzilly

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

1. Pharmaceutical Product Revenue: Igyxos is developing IGX12, a first-in-class monoclonal antibody therapeutic for infertility treatment. As a pre-revenue clinical-stage biotech, the company does not currently generate product revenue. Future revenue will come from commercialization of IGX12 for treatment of male and female infertility through fertility clinics and healthcare providers globally.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Igyxos is a clinical-stage biotechnology company developing IGX12, a first-in-class humanized monoclonal antibody therapeutic designed to enhance the bioactivity of Follicle Stimulating Hormone (FSH) for the treatment of infertility in both men (oligozoospermia) and women (ovarian stimulation for IVF/assisted reproduction). The antibody binds to both FSH and the FSH receptor, inducing conformational changes that significantly improve receptor binding and FSH receptor activation. Igyxos is currently pre-revenue with Phase 1 trials completed in 2025 and Phase 2 trials planned at European fertility centers in 2026.

Product overview

Igyxos is a clinical-stage biotechnology company developing a single therapeutic product, IGX12, a first-in-class potentiating monoclonal antibody designed to enhance FSH (Follicle Stimulating Hormone) activity for the treatment of infertility in both men and women. The company's approach addresses a significant unmet medical need, as there are currently no approved treatments for male infertility despite it accounting for approximately 50% of infertility cases. IGX12 operates through a novel mechanism of action that boosts FSH bioactivity, potentially reducing the number of injections required and improving treatment outcomes compared to standard FSH therapy. The company is advancing IGX12 through Phase 1 clinical trials with Phase 2 trials planned for 2026.

Differentiator

Problem solved

Functional benefit

Products and services

• IGX12 IGX12 is a first-in-class humanized monoclonal antibody (mAb) therapeutic designed to enhance the potency and efficacy of Follicle Stimulating Hormone (FSH). It binds to FSH and facilitates its interaction with the FSH receptor, resulting in increased receptor activation and improved gametogenesis. IGX12 targets treatment of infertility in both men (oligozoospermia) and women (IVF/assisted reproduction). Currently in Phase 1 clinical development with Phase 2 trials planned for 2026.

Quantifiable outcome

• Phase 1 SAD study completed in 32 healthy volunteers (16 men, 16 women) with excellent safety profile and no serious adverse events
• +4 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Nine partnerships are on record, tiered core and minor.

• CRS (Berlin)coreTechnology or Integration · 1 January 2023CRS was selected by Igyxos for the performance of its Phase 1 clinical studies which were initiated in 2023 at CRS Berlin, a dedicated phase I clinical trials unit.
• ERBCcoreTechnology or Integration · 1 January 2022From 2022, ERBC has been performing the toxicological studies in animals to support IGX12 entry into clinics.
• BaccinexcoreTechnology or Integration · 1 January 2021In 2021, Baccinex and Igyxos entered into a service agreement under which Baccinex produces IGX12 Drug Product for clinical studies.
• SelexiscoreTechnology or Integration · 2 September 2020In 2020, Selexis and Igyxos entered into a service agreement to utilize Selexis' proprietary SUREtechnology Platform to rapidly develop the cell line to advance IGX12 into human trials. Selexis, a JSR Life Sciences company and global leader in cell line development, provides high-expressing, stable, production-ready research cell banks.
• Merck Biodevelopment (EMD Millipore)coreTechnology or Integration · 1 January 2020In 2020, Merck and Igyxos entered into a service agreement to produce IGX12 to support pre-clinical and phase I/II clinical studies. Merck provides manufacturing services for the monoclonal antibody.
• Centre Val de LoireminorOthersRegional government support organization providing funding and support to companies in the Centre-Val de Loire region of France.
• AtlanpoleminorOthersRegional innovation and business development organization supporting companies in the Pays de la Loire region.
• INRAe (National Institute for Agricultural Research)minorOthersFrench national research institute. Igyxos is based at the INRAe Val de Loire site in Nouzilly, reflecting historical ties to reproductive health research conducted at INRA.
• INSERMminorOthersFrench National Institute of Health and Medical Research, a public research institute supporting biomedical research in France.

Scale indicators8 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Ferring Pharmaceuticals: Private global biopharma specializing in reproductive medicine and women's health (e.g., Menopur, Bravelle). Directly comparable as the established leader in fertility therapeutics that any novel FSH-potentiating mAb would compete against.
• Organon: Public women's health spinoff from Merck with a major fertility franchise (e.g., Follistim, Ganirelix). Directly comparable as a large reproductive-health incumbent whose commercial footprint and lifecycle management strategy IGX12 would need to challenge.
• Merck KGaA (Healthcare): Markets Gonal-f (recombinant FSH), the dominant gonadotropin in IVF. Directly comparable as the standard-of-care FSH therapy that IGX12 is designed to potentiate, and a likely commercial partner or competitive threat.
• Gedeon Richter: Hungarian-headquartered pharma with a meaningful women's health/fertility portfolio. Comparable as an established reproductive-medicine player that could pursue or partner a novel FSH-potentiating mechanism.
• Theramex: Private global women's health company with a fertility and reproductive endocrinology portfolio. Comparable as a focused reproductive-health commercial-stage player that could be a regional licensing/distribution partner for IGX12.

Direct peers

• ObsEva: Clinical-stage Swiss biotech developing women's health therapeutics for reproductive indications (Yselty for uterine fibroids/endometriosis). Directly comparable as a small-cap clinical-stage women's/reproductive health biotech in Europe, with similar partnership dynamics.
• Mereo BioPharma: London-listed clinical-stage biotech focused on rare diseases including women's health and reproductive indications. Comparable as a small European clinical-stage biotech with a similar partnership-and-pivot operating model.

Emerging players

• Evotec: European contract drug discovery and development company with active programs in reproductive health. Comparable as an enabling partner in the European biotech ecosystem, though positioned more as a service provider than a fertility asset developer.

Others

• PregLem: Swiss women's health biotech (now Gedeon Richter subsidiary) that developed Esmya (ulipristal acetate) for uterine fibroids, led by Dr. Elke Bestel (now Igyxos CMO). Comparable thematically as a women's reproductive-health biotech whose leadership now sits on Igyxos.
• Cellectis: French clinical-stage cell and gene therapy biotech. Comparable as a French clinical-stage biotech of similar vintage with comparable operational benchmarks, though unrelated in therapeutic area; Igyxos COO Thierry Ziegler previously led cell therapy production there.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/igyxos

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds2 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Igyxos